Id: | acc4700 |
Group: | 1sens |
Protein: | eNOS |
Gene Symbol: | NOS3 |
Protein Id: | P29474 |
Protein Name: | NOS3_HUMAN |
PTM: | phosphorylation |
Site: | Tyr81 |
Site Sequence: | KNWEVGSITYDTLSAQAQQDG |
Disease Category: | Endocrine and metabolic diseases |
Disease: | Diabetes Mellitus |
Disease Subtype: | Diabetic Endothelial Dysfunction |
Disease Cellline: | |
Disease Info: | |
Drug: | AKB-9778 |
Drug Info: | AKB-9778 is a drug. It may have specific pharmacological effects and applications in the medical field. |
Effect: | modulate |
Effect Info: | VE - PTP inhibition significantly reduces systolic and diastolic blood pressure in diabetic patients and improves endothelial function by increasing the phosphorylation of endothelial nitric oxide synthase (eNOS) at Tyr81 and Ser1177. |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 32653904 |
Sentence Index: | 32653904_12 |
Sentence: | "Finally, phosphorylation of eNOS on Tyr80 (murine sequence) was found to be reduced in diabetic mice and diabetes-induced endothelial dysfunction (isolated aortic rings) was blunted by VE-PTP inhibition." |
Sequence & Structure:
MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDDPPELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNSP
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
NOS3 | TILARGININE ACETATE | Nitric oxide synthase inhibitor | 3 | Terminated | Shock | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 3 | Terminated | Shock | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 2 | Terminated | anemia (phenotype) | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 2 | Completed | sickle cell anemia | ClinicalTrials ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 2 | Completed | hyperlipidemia | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Terminated | HIV infection | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Withdrawn | hypoxia | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | serum lipopolysaccharide activity | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | sarcopenia | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | breast cancer | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | sickle cell anemia | ClinicalTrials ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
NOS3-Ser114 | |
---|---|
Cancer | Intensity |
BRCA | 0.49 |
COAD | 0.793 |
HGSC | 1.744 |
ccRCC | 0.038 |
GBM | 0.046 |
HNSC | 0.481 |
LUAD | -1.558 |
LUSC | 0.7 |
non_ccRCC | -1.385 |
PDAC | -0.44 |
UCEC | -0.908 |
NOS3-Ser1177 | |
---|---|
Cancer | Intensity |
BRCA | 0.71 |
COAD | 0.399 |
HGSC | 1.182 |
ccRCC | 0.059 |
GBM | -0.83 |
HNSC | 0.225 |
LUAD | 0.965 |
LUSC | 0.783 |
non_ccRCC | -1.984 |
PDAC | -0.216 |
UCEC | -1.292 |
NOS3-Ser1179 | |
---|---|
Cancer | Intensity |
BRCA | 0.841 |
COAD | 0.511 |
HGSC | -1.163 |
ccRCC | 0.561 |
GBM | |
HNSC | |
LUAD | 0.712 |
LUSC | 0.986 |
non_ccRCC | -1.897 |
PDAC | -0.022 |
UCEC | -0.531 |
NOS3-Ser1202 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.707 |
HGSC | |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC | -0.707 |
NOS3-Ser39 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.707 |
HGSC | 0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser483 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | 0.707 |
GBM | |
HNSC | |
LUAD | -0.707 |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser53 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.337 |
HGSC | 1.385 |
ccRCC | -0.066 |
GBM | |
HNSC | |
LUAD | -0.982 |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser56 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.707 |
HGSC | |
ccRCC | 0.707 |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser57 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.707 |
HGSC | |
ccRCC | -0.707 |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser615 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.974 |
HGSC | 0.868 |
ccRCC | -0.967 |
GBM | |
HNSC | |
LUAD | -0.091 |
LUSC | |
non_ccRCC | 1.164 |
PDAC | |
UCEC |
NOS3-Ser617 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.627 |
HGSC | 1.153 |
ccRCC | -0.527 |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser624 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.707 |
HGSC | -0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser625 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.946 |
HGSC | -1.046 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC | 0.1 |
NOS3-Ser633 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.119 |
HGSC | 1.85 |
ccRCC | 0.021 |
GBM | |
HNSC | 0.016 |
LUAD | -0.891 |
LUSC | |
non_ccRCC | |
PDAC | -0.877 |
UCEC |
NOS3-Ser634 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.707 |
HGSC | |
ccRCC | 0.707 |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser638 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -1.15 |
HGSC | |
ccRCC | 0.661 |
GBM | |
HNSC | |
LUAD | |
LUSC | 0.49 |
non_ccRCC | |
PDAC | |
UCEC |
NOS3-Ser836 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | -0.615 |
GBM | |
HNSC | |
LUAD | 1.256 |
LUSC | |
non_ccRCC | -0.968 |
PDAC | |
UCEC | 0.327 |
NOS3-Thr1175 | |
---|---|
Cancer | Intensity |
BRCA | 0.582 |
COAD | 0.281 |
HGSC | 1.827 |
ccRCC | -0.067 |
GBM | -1.23 |
HNSC | 0.078 |
LUAD | 0.282 |
LUSC | 0.653 |
non_ccRCC | -2.023 |
PDAC | -0.345 |
UCEC | -0.036 |
NOS3-Thr33 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.551 |
HGSC | 1.449 |
ccRCC | 0.591 |
GBM | |
HNSC | |
LUAD | -0.842 |
LUSC | |
non_ccRCC | -0.944 |
PDAC | |
UCEC | -0.805 |
NOS3-Thr636 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.617 |
HGSC | 1.154 |
ccRCC | -0.536 |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.